FDA approves atezolizumab in combination with chemotherapy for Stage III mismatch repair deficient c

FDA approves atezolizumab in combination with chemotherapy for Stage III mismatch repair deficient colon cancer

On October 8, 2026, the Food and Drug Administration approved atezolizumab (Tecentriq, Genentech, Inc.) in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of adult and pediatric patients two years of age and older with Stage III mismatch repair deficient (dMMR) colon c

http://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-atezolizumab-combination-chemotherapy-stage-iii-mismatch-repair-deficient-colon-cancer fda.gov

RSS Hunter • Oct 8